Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jan 22;16(1):e0245619. doi: 10.1371/journal.pone.0245619

Effect of periodontal treatment on the glomerular filtration rate, reduction of inflammatory markers and mortality in patients with chronic kidney disease: A systematic review

Théo Delbove 1,2,3, François Gueyffier 4, Laurent Juillard 5, Emilie Kalbacher 5, Delphine Maucort-Boulch 6, Patrice Nony 4, Brigitte Grosgogeat 1,2,7, Kerstin Gritsch 1,2,3,*
Editor: Bhagwan Dass8
PMCID: PMC7822280  PMID: 33481920

Abstract

Aim

To assess the effect of periodontal treatment (PT) on glomerular filtration rate (GFR), systemic inflammation, or mortality in patients with chronic kidney disease (CKD).

Methods

A literature search was performed on PubMed and Web of Science databases on articles published until December 2019. The PRISMA guidelines were used throughout the manuscript.

Results

Of the total studies found, only 18 met the inclusion criteria; four retrospective and 14 prospective studies (including 3 randomized controlled trials–RCT). After PT, 3 studies investigated GFR, 2 found significant improvement; 11 (including 2 RCTs) investigated C-reactive protein levels, 9 found a significant improvement (including the 2 RCTs); 5 (including 3 RCTs) investigated Interleukine-6 level, 4 found a significant improvement (including 2 RCTs) and 2 studies evaluated mortality, one (retrospective study) found a significant difference.

Conclusions

Within the limitations of the present study, PT seems to improve CKD status, especially by reducing the systemic inflammation. Further RCTs are needed to confirm the results and specifically assess the influence of different types of PT in CKD patients. Taking into consideration the ability of PT to prevent further tooth loss and denutrition, early management of periodontitis is extremely important in patients with impaired renal function.

Introduction

Periodontitis is an immune-mediated inflammatory disease that is due to bacterial infection (periodontal flora), leading to the destruction of the tissues surrounding the tooth (periodontium). The global prevalence of its severe forms has been estimated to 10.8%, affecting 743 million people worldwide [1]. Both innate and adaptive immune responses are stimulated by the periodontal bacteria [2] and the release of bacterial products and inflammatory mediators from periodontal pockets result in low-grade systemic inflammation [3, 4]. Periodontitis has been most strongly associated with an increase of pro-inflammatory cytokines levels [5] and serum C-reactive protein (CRP) levels [6]. Moreover, the relationship between periodontitis and some systemic diseases has been well documented (for example periodontitis and diabetes [7, 8], periodontitis and cardiovascular diseases [9, 10]). There is also strong evidence supporting a positive association between periodontitis and chronic kidney disease (CKD) [1113], and some studies suggest a more severe periodontal breakdown with the progression of kidney disease [14, 15], and the duration of dialysis therapy [16]. Furthermore, the risk of death is higher in haemodialysis (end-stage renal disease) patients with periodontitis than those without periodontitis [17, 18]. If relationship between these two diseases is often described, recent meta-analysis concluded that there is a need to determine whether prevention of periodontal disease or periodontal treatment can reduce the severity of CKD [11, 19]. CKD is related to many specifics markers: diagnostic of CKD is based on the glomerular filtration rate (GFR) levels, also CKD have an influence in inflammatory markers, and is related to death due to cardio-vascular disease. We aimed to systematically review all prospective and retrospective studies assessing the effect of periodontal treatment in CKD using clinical parameters, in patients suffering of periodontitis.

Materials and methods

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) [20] were used as a guideline throughout the manuscript and the protocol was registered in the international prospective register of systematic reviews (PROSPERO; registration number CRD42017075376).

Study selection

The inclusion criteria were: at least one group of patients with periodontitis and CKD at any stage, including end-stage-renal disease (ESRD); any kind of PT, including oral hygiene instruction, nonsurgical or surgical treatment; and at least one of the following–renal function evaluation (i.e. GFR), inflammatory marker, or mortality.

Search strategy

A literature search was performed using two electronic databases (PubMed & Web of Science) on articles published until December 2019. Language restrictions were not applied. The keywords used in the electronic search (in “Title/Abstract” for MEDLINE database and “Topic” for Web of Science database) were as follows: periodont* AND (oral hygiene OR root planing OR treatment OR therapy) AND (end-stage renal disease OR renal failure OR chronic kidney disease OR hemodialysis OR dialysis)

Authors (TD, KG) independently reviewed and screened the title and abstract of potentially relevant records and determined final eligibility through examination of full texts. Citations were screened for additional publications that were missed by the electronic search. Review articles and short communications were excluded. Disagreements were resolved through discussion.

Data collection

Our analysis focused for each study on the protocol parameters, the assessment criteria, the comparison groups, and the biological and clinical results. To determine the bias of studies, the Cochrane risk of bias tool was used for RCTs [21]; two reviewers (TD, PN) assigned a judgment of high, low, or unclear risk of material bias for each item independently. Discrepancies about risk of each risk of bias have been resolved by discussion in the first instance; where consensus could not be reached, a third reviewer was consulted. The quality of each non-randomized study (including at least one control group) was evaluated using the Newcastle-Ottawa Scale [22]. This scale includes 3 categorical criteria with a maximum score of 9 points: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. The quality of each study was rated using the following scoring algorithms: ≥7 points was considered as “high”, 4 to 6 points was considered as “moderate”, and ≤3 point was considered as “poor” quality study.

Results

Study selection

The search identified 369 records. After removal of duplicates 277 records remained and the title and abstract of these records were assessed. A total of 257 records were rejected because they did not meet the inclusion criteria. The remaining 20 underwent full text examination: one article did not meet the inclusion criteria (publication of a future study protocol) [23] and one article was a short communication [24]; 18 studies were finally included (Fig 1) [2542].

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Fig 1

Study characteristics

Type of studies

Among the 18 included studies, 4 were retrospective [3942], and 14 were prospective studies [2538] including 3 RCTs (Table 1) [27, 29, 34].

Table 1. Characteristics of the 18 included studies.
Author, year Experimental group (number of patients) Control group (number of patients) Periodontal Treatment Assessed criteria Main results Study design and other methological aspects
Rapone et al. [25] ESRDa + PD + PT (n = 66) - Non surgical periodontal treatment (mechanical supra- and sub-gingival debridement and root planing by quadrant using hand and ultrasonic instruments under local anaesthesia. performed at baseline and at 3 months. Folow-up at 3 and 6 months. Serum albumin (mg/dL)
Serum creatinine (mg/dL)
CRP
PI (Löe)
BoP
PD (mm)
CAL (mm)
At 3 months after PT
All periodontal parameters were improved vs baseline (p<0.001).
There was significant correlation between PI and CRP (p = 0.012), BoP and CRP (p = 0.002) and CAL and CRP (p = 0.022).
There was no significant correlation between periodontal parameters and albumin and creatinine levels.
At 6 months after PT
Serum albumin decreased vs baseline (p<0.001).
Serum creatinine increased vs baseline (p = 0.002).
All periodontal parameters were improved vs baseline (p<0.001).
There was significant correlation between PI and CRP (p<0.001), BoP and CRP (p<0.001).
There was no significant correlation between periodontal parameters and albumin and creatinine levels.
Cohort study
No control group
Single center study
Type I error rate inflation
Exploratory results
Tasdemir et al. [26] CKDb + Diabetes + PD + PT (n = 20) (1) PD + PT (n = 20)
(2) Diabetes + PD + PT (n = 20)
All groups received standard oral hygiene instruction and full-mouth scaling and root planing (protocol performed based on Quirynen et al. 1995). Oral hygiene control and reinstructions were provided during all visits. Scaling and root planing was repeated if necessary at the end of the study. During the PT sessions, necessary tooth extractions were performed and referrals for endodontic and restorative treatments were given immediately after PT was completed. TNF-α (pg/mL)
IL-6 (pg/mL)
PTX-3 (ng/mL)
Hs-CRP
Ferritin
TC
HDL
LDL
HbA1c
Glucose
Insulin
Homa-Ir
Alb
Cr
BUN
PTH
Ca
Phosphorus serum
Uric acid
Hb
PI (Silness and Loë)
GI (Loë and Silness)
BOP (%)
PD (mm)
CAL (mm)
DMFT (index)
Decay (n)
Missing teeth(n)
Experimental group:
TNF-alpha, PTX-3, IL-6 and Hs-CRP values significantly decreased at 3 months after PT compared to baseline (p<0.001).
Glucose levels and Homa-Ir significantly decreased at 3 months after PT compared to baseline (p = 0.042 and p = 0.037, respectively).
All periodontal parameters were improved at 3 months after PT compared to baseline (p<0.001)
No significant changes were noticed for the other parameters compared to baseline.
Control group (1):
TNF-alpha values significantly decreased at 3 months after PT compared to baseline (p = 0.022).
All periodontal parameters were improved at 3 months after PT vs baseline (p<0.001).
No significant changes were noticed for the other parameters compared to baseline.
Control group (2):
TNF-alpha values significantly decreased at 3 months after PT compared to baseline (p = 0.037).
All periodontal parameters were improved at 3 months after PT vs baseline (p<0.001)
No significant changes were noticed for the other parameters compared to baseline.
All the periodontal parameters were similar at baseline in all groups. There were no significant differences among groups after at 3 months after PT.
Non randomized 3 groups study
Before/after clinical study,
Single center study
Significant differences in terms of gender among the groups
Type I error rate inflation
Exploratory results
Guo and Lin et al. [27] CKDc + PD + PT (n = 26) (1) PD + PT (n = 30)
(2) CKDa + PD + PT (n = 27)
Experimental group and control group (1): oral hygiene instruction and nonsurgical periodontal treatment (ultrasonic scaling, subgingival scaling and root planing)
Control group (2): oral hygiene instruction
hs-CRP (mg/L)
IL-6 (pg/ml)
TNF-α (pg/ml)
PPD (mm)
BOP (%)
CAL (mm)
Experimental group: for all assessed criteria, the values were significantly lower at 6 weeks after PT compared to baseline (p< 0.05).
Control group (1): for all assessed criteria, the values were significantly lower at 6 weeks after PT compared to baseline (p< 0.05).
Control group (2):
hs-CRP, BOP and CAL values were significantly lower at 6 weeks after PT compared to baseline (p< 0.05).
No significant changes were noticed for IL-6, TNF-α and PPD values before and after PT.
RCT
Single center study
Type I error rate inflation
Exploratory results
Almeida et al. [28] CKDd + PD + PT (n = 26) - Oral hygiene instruction and nonsurgical periodontal treatment (manual and sonic supragingival scaling, subgingival scaling and root planing) in four to six sessions for two weeks. Oral hygiene instruction reinforced at each session. eGFR (mL/min/1.73m2)
albumin(g/dL)
cholesterol (mg/dL)
TG (mg/dL)
ADMA (μmol/mL)
PI (%)
PPD (4-5mm) (% sites)
PPD (≥ 6mm) (% sites)
BOP (%)
CAL (4-5mm) (% sites)
CAL (≥ 6mm) (% sites)
At 3 months after PT
eGFR values significantly increased compared to baseline (p<0.01).
PI, PPD (4–5 mm), PPD (≥ 6mm), BOP, CAL (4-5mm) and CAL (≥ 6mm) values significantly decreased compared to baseline (p< 0.001).
No significant changes were noticed for albumin, cholesterol and ADMA values before and after PT.
At 6 months after PT:
eGFR values significantly increased compared to baseline (p<0.05).
ADMA values significantly decreased compared to baseline (p<0.05).
PI, PPD (4–5 mm), PPD (≥ 6mm), BOP, CAL (4-5mm) and CAL (≥ 6mm) values significantly decreased compared to baseline (p< 0.001).
No significant changes were noticed for albumin and cholesterol values before and after PT.
Cohort study
No control group
Single center study
Type I error rate inflation
Exploratory results
Fang et al. [29] ESRD + PD + PT (n = 48) ESRD + PD (n = 49) Experimental group: oral hygiene instruction, supra- and sub-gingival instrumentation (scaling and root planing) using ultrasonic and manual instruments completed within 24 hours. Teeth extraction if necessary. Supragingival prophylaxis at 3 months.
Control group: no therapy measures or formal oral hygiene instructions
hs-CRP
IL-6 (pg/ml)
albumin (g/dl)
HDL-C (mmol/l)
LDL-C (mmol/l)
Tf (g/l)
TG (mmol/l)
BUN (mg/dl)
nPCR (g/kg/day)
Cr (mg/dl)
TNF-α (pg/ml)
ALC (103/μl)
PI (Silness and Loë)
PPD (mm)
BOP (%)
CAL (mm)
At 6 weeks after PT:
hs-CRP values decreased compared to baseline and were lower to those of the control group without significance (p = 0.196).
Compared to baseline values, albumin, Tf and BUN values significantly increased (p<0.05) whereas TNF-α values decreased (p<0.05).
For HDL-C and Cr values, results showed an increase compared to both baseline and control group values (p<0.05).
No significant changes were noticed for IL-6, LDL-C, TG, nPCR and ALC values before and after PT or compared to the control group.
All periodontal parameters values significantly decreased compared to baseline and to the control group (p<0.05).
At 3 months after PT:
hs-CRP values decreased compared to baseline and were significantly lower to those of the control group (p < 0.01).
Compared to both baseline and control group values, significant differences (p<0.05) were noticed for IL-6 values (decrease) and for albumin, Tf, BUN and Cr values (increase).
No significant changes were noticed for HDL-C, LDL-C, TG, nPCR, TNF- α and ALC values before and after PT or compared to the control group.
All periodontal criteria values significantly decreased compared to baseline (p<0.05).
At 6 months after PT:
Same results than after 3 months with values even lower for hs-CRP compared to the control group (p<0.001) and all periodontal criteria significantly decreased compared to baseline and control group values (p < 0.05).
RCT
Single center study
For primary endpoint, no statistical analysis specific to repeated measurements
Type I error rate inflation for secondary endpoints
De Souza et al. [30] ESRD + PD + PT (n = 43) (1) ESRD+ PD (n = 30)
(2) ESRD (n = 49)
Experimental group: Oral hygiene instruction, antibiotic prophylaxis (2g amoxicillin), and scaling and root planing using hand and ultrasonic instrumentation. Variable number of follow-up visits with additional treatment.
Control group (1): patients that were invited to receive treatment but did no show up for the treatment visits
Fatal events 34 fatal events during the follow-up time (mean 64.1 ± 11.2 months): 15 for experimental group, 11 for control group (1) and 8 for control group (2).
No significant differences between the groups, after adjustments for confounders in the multivariate model.
Prospective operational study
Observational study
Single center study
Exploratory results
Kocyigit et al. [31] ESRD+ PDe + PT (n = 43) - Oral hygiene instructions (alone for healthy patients), full-mouth scaling and root planing with periodontal curettes and ultrasonic intrumentation in 2 or 4 sessions. Patients instructed to rinse twice daily for 1 min with 0.12% solution of chlorhexidine digluconate for 14 days. During PT, necessary tooth extractions were performed. hs-CRP (mg/L)
White blood cell count
Hemoglobin (g/dL)
Fasting glucose (mg/dL)
Total cholesterol (mg/dL)
Triglyceride (mg/dL)
LDL cholesterol (mg/dL)
HDL cholesterol (mg/dL)
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum albumin (g/dL)
Transferrin saturation (%)
hs-CRP (mg/L)
Intact parathormone (pg/mL)
Kt/Vurea
Plaque index
Gingival index
Pocket depth
Bleeding on probing (%)
Clinical attachment loss
Gingival recession
At 3 months after PT
Healthy/gingivitis:
No significant changes were noticed for all parameters
Slight-to-moderate periodontitis:
hs-CRP values decreased compared to baseline
CAL and PI decrease compare to baseline (p = 0.014)
No significant changes were noticed for the other parameters.
Severe periodontitis:
hs-CRP values decreased compare to baseline (p = 0.001)
CAL and PI decrease compare to baseline (p = 0.001)
No significant changes were noticed for the other parameters.
Comparison according to severity of PD:
Significant difference between healthy/gingivitis and slightly moderate periodontitis groups for White blood cell count (p = 0.031).
Hs-CRP, GI, PPD, CAL, Gingival recession, showed significant difference between healthy/gingivitis and slightly moderate (p = 0.023) and severe periodontitis groups (p<0.001).
Cohort study
Observational study
Single center study
Exploratory results
Siribamrungwong et al. [32] ESRDf+ PD + PT (n = 15) - Oral hygiene instruction and nonsurgical periodontal treatment (scaling, root planning and curettage in patients presenting teeth with periodontitis). Surgical treatment consisting of gingivectomy or gingivoplasty 6 months after the non-surgical phase in patients presenting teeth with attachment loss ≥ 3 mm hs-CRP (mg/L)
Ferritin (ng/mL)
Blood urea nitrogen (mg/dL)
Albumin (g/dL)
Total cholesterol (mg/dL)
Hemoglobin (g/dL)
Calcium (mg/dL)
Phosphate (mg/dL)
Parathyroid hormone (pg/mL)
Transferrin saturation (%)
Kt/Vurea
nPCR
Erythropoietin dosage (unit/week)
PI (plaque index)
PDI (periodontal disease index)
At 16 weeks after PT:
Compared to baseline values, hs-CRP and erythropoietin values significantly decreased (p<0.05) whereas blood urea nitrogen values increased (p<0.05).
Periodontal parameters were significantly improved.
Interventional uncontrolled study
Observational study
Single center study
Exploratory results
Yazdi et al. [33] ESRD + PDg + PT (n = 77) - According to the need of each patient: oral hygiene instruction, scaling and root planing with ultrasound devices and manual instruments, polishing, and subgingival curettage in 1h sessions repeated according to the need of each patient.
Teeth extraction and restoration of carious lesions if needed. A follow-up program was carried out based on the need of the patients (additional ora hygiene instructions and supragingival prophylaxis)
hs-CRP (mg/L) At 8 weeks after initial PT :
CRP values showed significant reduction compared to baseline (p< 0.001).
No significant relation was found between this difference and the severity of periodontitis.
Interventional uncontrolled study
No control group
Single center study
Exploratory results
Wehmeyer et al. [34] ESRD + PD + PT (n = 25) ESRD + PD (n = 26) Scaling and root planig under local anesthesia using hand and ultrasonic instruments. Adjunctive local-delivery antimicrobial therapy with controlled-release microsphere-encapsulated biodegradable minocycline to all sites > 5-mm probing depths (at the time of instrumentation and at the 3- and 6-months follow-up appointments).
Teeth extraction at the time of scaling and root planning. Treatment done in 1 or 2 appointments. All participants received verbal and written oral hygiene instruction at each visit (instructions and demonstrations).
Experimental group: follow-up examinations at 3 and 6 months after completion of treatment
Control group: follow-up examinations at 3 and 6 months after baseline (received treatment at the conclusion of the study)
Serum albumin
hs-IL-6 (pg/mL)
Probing depth
Clinical attachement level
Bleeding on probin
Gingival index
Plaque index
At 3 months after PT:
No statistical differences for serum albumin or hs-IL-6 level between the groups.
About periodontal criteria, statistically significant improvement for the treatment group compared to the control group for the following periodontal parameters: probing depth (p> 0.05), extent of probing depth ≥ 4 mm (p < 0.05), extent of gingival index ≥ 1 (p = 0.01).
At 6 months after PT:
No statistical differences for serum albumin or hs-IL-6 level between the groups.
About periodontal criteria, statistically significant improvement for the treatment group compared to the control group for extent of probing depth ≥ 4 mm only (p < 0.05).
RCT
Pilot RCT
Patients poorly representative
Type I error rate inflation
Exploratory results
Siribamrungwong et al. [35] ESRDh+ PD + PT (n = 30 ; 63% of presenting periodontitis) - Same as Siribamrungwong et al. [31] hs-CRP (mg/L)
Ferritin (ng/mL)
Blood urea nitrogen (mg/dL)
Albumin (g/dL)
Total cholesterol (mg/dL)
Hemoglobin (g/dL)
Hematocrit (%)
Total leukocyte count (μL-1)
Calcium (mg/dL)
Phosphate (mg/dL)
Parathyroid hormone (pg/mL)
Transferrin saturation (%)
Kt/Vurea
nPCR
Erythropoietin dosage (unit/week)
PI (plaque index)
PDI (periodontal disease index)
After completion of periodontal therapy (duration 6 ± 2 weeks):
Significant decrease of hs-CRP (p < 0.001) and erythropoeitin (p< 0.01), and significant increase of blood urea nitrogen (p< 0.01) and albumin (p< 0.001).
No statistical differences (p< 0.05) observed in the other parameters.
Significantly decrease of periodontal indices; PI (p = 0.001), PDI (p = 0.001).
Interventional uncontrolled study
No control group
Single center study
Exploratory results
Vilela et al. [36] CKDi + PD + PT (n = 36) PD + PT (n = 20) Both groups received oral hygiene instructions. Radicular scraping and subgingival curettage were performed with manual and ultrasound devices in 1-hour sessions over an average period of 4 weeks for non surgical treatment. Follow-up after 15, 30, 60 and 90 days: instructions on oral hygiene and supragingival prophylaxis. Prohepcidin (ng/mL)
IL-6 (pg/mL)
us-CRP (mg/L)
Serum Fe (μg/dL)
TSat (%)
Ferritin (ng/dL)
Hemoglobin (g/dL)
BOP (%)
PPD (mm)
CAL (mm)
GI
PI
Sites with PPD ≥ 5 mm (n)
At baseline:
PD was more severe in patients in the experimental group.
At 3 months after completion of PT:
In both groups, significantly decreases were observed for the following parameters ; prohepcidin (p < 0.05 and p < 0.01 for experimental and control groups, respectively), IL-6 (p < 0.01 and p < 0.05 for experimental and control groups, respectively) and us-CRP (p < 0.01 and p < 0.05 for experimental and control groups, respectively).
In the control group, a significant increase in the levels of hemoglobin (p < 0.05) and ferritin (p < 0.05) was also observed.
In both groups, significant improvement in periodontal parameters were noticed (p < 0.05) ; BOP, PPD, CAL, GI, PI, sites with PPD ≥ 5 mm.
Interventional controlled
non-randomized
Non-randomized trial
Single center study
Exploratory results
Artese et al. [37] CKDj + PD + PT (n = 21) PD + PT (n = 19) Both groups received non-surgical treatment consisting of oral hygiene instructions, scaling and root planning (manual instrumentation), under local anesthesia, by sextant for each dental visit completed over a 6–8 week period for the entire mouth. GFR (Cockcroft and Gault equation, multiplied by 0.85 for female patients)
Serum creatinine
GB (Gingival bleeding index, % of sites)
VP (Visible plaque index, % of sites)
SUP (suppuration, % of sites)
BOP (bleeding on probing, % of sites) PD (Probing depth 1-3mm, 4-6mm, ≥ 7mm, % of sites) AL (attachment loss 1-3mm, 4-6mm, ≥ 7mm, % of sites)
At 3 months after PT:
Statistically significant improvement of GFR was observed in the experimental group (p < 0.05) and in the control group (p < 0.01). No significant differences were noticed in both groups for Creatinine levels.
Both groups experienced a significant improvement in many of the periodontal parameters measured, without significant differences between the groups.
Interventional controlled
non-randomized
Non-randomized trial
Single center study
Exploratory results
Kadiroglu et al. [38] ESRDk + PD + PT + high CRP level (n = 21, 48% gingivitis/52% peiodontitis) - All patients received standard oral hygiene instructions before the first session of scaling and root planning (non-surgical therapy). Sessions performed once a week for a month (standard periodontal curettes and an ultrasonic device starting 1 day after the HD session). CRP (mg/l)
ESR (Erythrocyte sedimentation rate, mm/h)
Ferritin (ng/mL)
Leukocyte (K/UL)
rHuEPO (U/week)
Hemoglobin (g/dL)
Hematocrit (%)
At 4–6 weeks after PT:
Significant decrease of CRP level and erythrocyte sedimentation rate (p = 0.001) and significant increase of hemoglobin level and hematocrit level (p< 0.01).
Interventional
Non-randomized study
No control group
Single center study
Exploratory results
No results about periodontal parameters after PT
Santos-Paul et al. [39] ESRD + PD + PT (n = 206) ESRD (n = 203) Debridement of the affected root surfaces or tooth extraction and any type of treatment considered suitable (plaque control, caries, endodontic intervention). Prophylactic antibiotics were not used. All patients were given instructions in basic oral hygiene. Patients were then referred to generalists for continuing dental health assessment and were followed-up for 24 months or until death or renal transplantation. Incidence of cardiovascular events and death Periodontal treatment was associated with reduction in cardiovascular events (HR 0.43; 95% CI 0.22–0.87), coronary events (HR 0.31; 95% CI 0.12–0.83), and cardiovascular deaths (HR 0.43; 95% CI 0.19–0.98). Single center observational cohort study.
Comparison with historical controls.
Periodontal status not assessed in the historical control group
Patients in the experimental group were younger. More patients received beta-blockers or renin-angiotensin system inhibitors in the control group.
Type I error rate inflation
Exploratory results
Huang et al. [40] ESRD + PD + PT (n = 3613) ESRD (n = 3613) Subgingival curettage, (scaling and root planing) and periodontal flap surgery. Incidence of cardiovascular diseases and mortality Compared with the comparison cohort, the adjusted hazard ratio of hospitalization for cardiovascular diseases was 0.78 (95% confidence interval = 0.73–0.84, p<0.001) in the treatment cohort. The treatment cohort exhibited significantly lower cumulative incidences of cardiovascular diseases and mortality. Retrospective observational cohort study
All useful information not available in the NHIRD, low number of PD patients who received no PT.
Periodontal status unclear in the control group.
Type I error rate inflation Exploratory results
Huang et al. [41] ESRD + PD + PT (n = 4451) ESRD (n = 4451) Subgingival curettage, (scaling and root planing) and periodontal flap surgery. Hospitalization for infectious disease The intensive PD treated cohort had a significantly lower risk of acute and subacute infective endocarditis (HR = 0.54, 95% CI = 0.35–0.84, p<0.01), pneumonia (HR = 0.71, 95% CI = 0.65–0.78, p<0.001), and osteomyelitis (HR = 0.77, 95% CI = 0.62–0.96, p<0.05) Retrospective study
Periodontal status unclear in the control group
Lee et al. [42] PD + PT (n = 35496) Treatment cohort PD (n = 141824) No-treatment cohort Subgingival curettage and/or periodontal flap surgery Incidence and risk of ESRD The overall incidence of ESRD was 37% lower in the treatment cohort than in the no-treatment cohort (4.66 vs 7.38 per 10000 person-years), with an adjusted HR of 0.59 (95% CI = 0.46 to 0.75). Retrospective study

CKD: Chronic Kidney Disease, ESRD: end-stade renal disease, PD: Periodontal disease, PT: Periodontal treatment, RCT: Randomized clinical trial.

areceiving hemodialysis for at least one year

bcontinuous ambulatory peritoneal dialysis with diabetic nephropathy

cincluding ESRD

dCKD stages 3 and 4

eparticipants classified as healthy/gingivitis, slight-to-moderate and severe periodontitis

fstable peritoneal dialysis

gparticipants classified as gingivitis, mild, moderate and severe periodontitis

hstable hemodialysis

iCKD patients at stages 3 to 5 undergoing conservative treatment

jCKD patients at stages 2 to 4 undergoing conservative treatment

karterioveinous fistula, patients on rHuEPO therapy.

Study design

There were 17 studies that had an experimental group mixing renal disease, periodontitis and periodontal treatment [2541], and one had a treatment cohort combining periodontitis and periodontal treatment and assessed the incidence and risk of ESRD in this group [42].

In prospective studies, seven did not include control groups [25, 28, 3133, 35, 38], while the remaining 7 had at least one control group [26, 27, 29, 30, 34, 36, 37] with 3 studies including two control groups [26, 27, 30]. In these 7 studies including control groups, the experimental groups consisted of patients with renal disease (different stages), periodontitis and periodontal treatment [27, 29, 30, 34, 36, 37] or of patients with diabetes, dialysis, periodontitis and periodontal treatment [26]. In those studies, the control groups consisted of patients with periodontitis and periodontal treatment without renal disease in 4 studies [26, 27, 36, 37], patients with renal disease and periodontitis in 3 studies [29, 30, 34], patients with renal disease, periodontitis and periodontal treatment limited to oral hygiene instructions in 1 study [27], patients with diabetes, periodontal disease and periodontal treatment in one study [26] or patients with renal disease in the last study [30].

In the retrospective studies, three estimated the risk of complications of patients with end-stage renal disease, periodontitis and periodontal treatment (experimental group) versus end-stage renal disease (control group) [3941] and the other estimated the incidence and risk of ESRD in patients with periodontitis and periodontal treatment (experimental group) versus patients with periodontal disease only (without periodontal treatment) (Table 1) [42].

Primary endpoint

The primary endpoint of 9 studies was systemic inflammation: eight studies evaluated this using CRP or high-sensitivity CRP (hs-CRP) levels [27, 29, 3133, 35, 36, 38] and 1 study evaluated this using interleukin-6 [34]. Five studies [30, 3942] focused on clinical outcomes; ESRD incidence [42], the risk of hospitalization for an infectious disease [41] or cardiovascular diseases [39, 40], and mortality [30, 39, 40]. For 2 studies [28, 37], the main assessment criterion was the GFR estimated from the Modification of Diet in Renal Disease (MDRD) [28] or the Cockcroft and Gault equation [37]. Two studies did not define primary endpoint (Table 2) [25, 26].

Table 2. Assessment criteria and improvement after PT compared to baseline in prospective studies.
Criteria / Authors Rapone et al. [25]a Tasdemir et al. [26]a Guo and Lin [27]b Almeida et al. [28] Fang et al. [29]b De Souza et al. [30] Kocyigit et al. [31] Siribamrungwong et al. [32] Yazdi et al. [33] Wehmeyer et al. [34]b Siribamrungwong et al. [35] Vilela et al. [36] Artese et al. [37] Kadiroglu et al. [38] Number of studies
Mortality ns60m 1
hs-CRP ns3,6m ***3m *6w ns6w NC *3m *16w ***8w ***6w *3m ***6w 11
**3m
***6m
IL-6 ***3m *6w ns6w ns3,6m **3m 5
*3,6m
eGFR **3m NC **3m 3
*6m
Albumin ***6m ns3m ns3,6m *6w,3,6m NC ns3m ns16w ns3,6m ***6w NC 10
HDL c ns3m ns3,6m *6w ns3m ns16w ns6w ns6w 7c
ns3,6m
LDL c ns3m ns6w, 3,6m ns3m
Tf *6w,3,6m ns3m ns16w ns6w *3m NC 6
Phos ns3m NC ns3m ns16w ns6w NC 6
Hg ns3m NC ns16w ns6w *3m **6w 6
Cal ns3m NC ns3m ns16w ns6w NC 6
PTH ns3m NC ns3m ns16w ns6w 5
Fer ns3m ns16w ns6w *3m NC 5
TC ns3m ns6m ns6w, 3,6m ns3m 4
BUN ns3m *6w, 3,6m *16w **6w 4
nPCR Ns6w,3,6m ns16w ns6w 3
Cr **6m ***3m ***6w, 3,6m ns3m 4
TNF-a ***3m *6w *6w ns3,6m 3
PTX-3 ***3m 1
ADMA ns3m *6m 1
ALC ns6w, 3,6m 1
Hct **6w 1

Primary endpoint always first on column for each study for clear reading, except for Rapone et al. and Tasdemir et al.; p value for improvement after periodontal treatment compared to baseline: ns non significant

*p<0.05

**p<0.01

***p<0.001, NC not communicated after periodontal treatment, w week m month

hs-CRP: high sensivity C reactive protein, eGFR: estimated glomerular filtration rate, IL-6: interleukin 6, HDL: high density lipoprotein, LDL: low density Lipoprotein, Hg: Hemoglobin, Phos: phosphate, Tf: transferrin, PTH: parathyroid hormone, Cal: calcium, Fer: ferritin, TC: triglycerid, BUN: blood urea nitrogen, nPCR: normalized protein catabolism, Cr: creatinine, TNF-a: tumor necrosis factor alpha Hct: hematocrit, PTX-3: pentraxin-3, ADMA: asymmetric dimethylarginine, ALC: absolute lymphocyte counts

aDo not defined primary endpoint

bRCT studies

c Cholesterol or HDL & LDL

Assessment of renal disease and systemic inflammation

To evaluate the impact of periodontal treatment on CKD, the included prospective studies evaluated 22 different criteria related to renal dysfunction and/or systemic inflammation (Table 2); the most frequently evaluated was CRP (11 studies), followed by albumin (10 studies), cholesterol (high/low-density lipoprotein, HDL/LDL) (7 studies), transferrin (6 studies), haemoglobin (6 studies), phosphate (6 studies), calcium (6 studies), parathyroid hormone (5 studies), ferritin (5 studies), IL-6 (5 studies), triglycerides (4 studies), blood urea nitrogen (4 studies), creatinine (4 studies), eGFR (3 studies), normalized protein catabolism (3 studies), tumour necrosis factor alpha (3 studies), pentraxin-3 (1 study), haematocrit (1 study), absolute lymphocyte counts level (1 study), asymmetric dimethylarginine (1 study), and mortality (1 study). The number of criteria assessed per study ranged from 1 [33] to 15 [26] (Table 2).

Periodontal assessment criteria and periodontal treatment efficacy evaluation

For 9 of the 14 prospective studies [2731, 33, 34, 36, 37], diagnosis of periodontitis was conducted by consensus with general chronic periodontitis defined as a CAL >4mm on 30% of affected sites [43]. Three studies [32, 35, 38], including two from the same team, used another system for diagnosis that was based on periodontal disease index (PDI) [44]. For one study [26], the clinical diagnosis of chronic periodontitis was based on the following criteria [45]; the presence of ≥ 5 teeth with ≥ 1 sites with probing depth ≥ 5 mm, clinical attachment level ≥ 2 mm, and the presence of bleeding on probing. For the last study [25], the diagnosis of periodontitis was performed according to the criteria of the American Academy of Periodontology (2017). Among the 14 prospective studies, 11 also evaluated the efficacy of the purposed periodontal treatment, measuring plaque index (PI) [25, 26, 28, 29, 31, 32, 3437], gingival index (GI) [26, 31, 34, 36, 37], probing pocket depth (PPD) [2529, 31, 34, 36, 37], bleeding on probing (BOP) [2529, 31, 34, 36, 37], clinical attachment level (CAL) [2529, 31, 34, 36, 37], or periodontal disease index (PDI) [32, 35]. Among these 11 studies, 4 showed a significant improvement of 2 criteria or less [31, 32, 34, 35], and 7 of 3 or more criteria (Table 3) [2529, 36, 37].

Table 3. Periodontal criteria and periodontal treatment evaluation after PT in experimental group compared to baseline in prospective studies.
Criteria / Authors Rapone et al. [25] Tasdemir et al. [26] Guo and Lin [27]a Almeida et al. [28] Fang et al. [29]a De Souza et al. [30] Kocyigit et al. [31] Siribamrungwong et al. [32] Yazdi et al. [33] Wehmeyer et al. [34]a Siribamrungwong et al. [35] Vilela et al. [36] Artese et al. [37] Kadiroglu et al. [38] Number of studies
PI ***3,6m ***3m ***3,6m *6w, 3,6m NC **3m *16w NC ns3,6m ***6w *3m ***3m NC 10
GI ***3m NC ns3m **3m *3m *3m NC 5
-6m
PPD ***3,6m ***3m *6w ***3,6m *6w, 3,6m NC ns3m *3,6m *3m ***3m NC 9
BOP ***3,6m ***3m *6w ***3,6m *6w, 3,6m ns3m NC ns3,6m *3m ***3m 9
CAL ***3,6m ***3m *6w ***3,6m *6w, 3,6m NC **3m NC ns3,6m *3m ***3m 9
PDI **16w ***6w NC 2

a RCT studies; p value for improvement after periodontal treatment compared to baseline:—non significant

*p<0.05

**p<0.01

***p<0.001, NC not communicated after periodontal treatment, w: weeks, m: months

PI: plaque index, GI: gingival index, PPD: probing pocket depth, BOP: bleeding on probing, CAL: clinical attachment level, PDI: periodontal dental index

For the 4 retrospectives studies [3942], the authors included patients who underwent for periodontal treatment. No evaluation of the periodontal treatment effectiveness was mentioned.

Clinical outcomes

Among the 11 studies evaluating CRP levels, 9 showed a significant improvement after periodontal treatment either with respect to baseline [26, 27, 29, 3133, 35, 36, 38] or to a control group [29]. For IL-6 level, 4 studies (on 5 studies) showed a significant decrease after periodontal treatment compared to baseline [26, 27, 29, 36]. RCT studies comparing experimental groups (ESRD and periodontitis and PT) to control groups (ESRD and PT) were Fang et al. [29] and Wehmeyer et al. [34]. At 3 and 6 months after completion of periodontal treatment, a significant decrease of IL-6 level was demonstrated in the first study [29] whereas no significant differences were observed in the second one (Table 1) [34].

The two studies investigating GFR as primary endpoint found a significant increase after periodontal treatment as compared to baseline [28, 37] without significant differences between the experimental group (CKD and periodontitis and PT) and the control group (PD and PT) (Table 1) [37].

Among the 4 retrospective studies, one found that the incidence of ESRD was 37% lower in the treatment group (PD and PT) than in the non-treatment group (PD without PT) with an adjusted HR of 0.59 (95% CI = 0.46 to 0.75) [42], and the three other found that patients with ESRD and periodontitis receiving periodontal treatment had a significantly lower risk of acute and subacute infective endocarditis, pneumonia, and osteomyelitis [41], and of cardiovascular diseases and mortality [39, 40] than patients with ESRD only (Table 1).

In the prospective study investigating the effect of treatment on fatal events, no significant difference was found between the groups after adjustments for confounders (Table 1) [30].

Risk of bias

Among the 14 prospective studies, 3 were RCTs [27, 29, 34], 4 included at least one control group [26, 30, 36, 37] and 7 had no control group [25, 28, 3133, 35, 38].

The 3 RCTs could be used for the Cochrane collaboration’s tool for assessing risk of bias in randomized trials. Two studies showed high risk of bias concerned blinding conditions (Table 4) [27, 34].

Table 4. Cochrane risk of bias tool's table (RCT studies).

Authors Random sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective reporting Other sources of bias
Guo et al. [27] unclear unclear high high low unclear low
Fang et al. [29] low low unclear unclear low low low
Wehmeyer et al. [34] low low high unclear low low low

According to the Newcastle-Ottawa Scale, the quality of the 4 prospective studies including at least one control group and of the 4 retrospective studies were considered as moderate quality [26, 30, 37] and the others as high quality [36, 3942] (Table 5).

Table 5. Newcastle-Ottawa quality assessment scale (studies including control groups).

Study Study design Selection Comparability Outcome Total
A B C D E F G H
Tasdemir et al. [26] Prospective 1 1 1 0 0 1 1 1 6
De Souza et al. [30] Prospective 1 1 1 1 0 1 1 0 6
Vilela et al. [36] Prospective 1 1 1 0 1 1 1 1 7
Artese et al. [37] Prospective 1 1 1 0 0 1 1 1 6
Santos-Paul et al. [39] Retrospective 1 1 1 1 0 1 1 1 7
Huang et al. [40] Retrospective 1 1 1 1 1 1 1 1 8
Huang et al. [41] Retrospective 1 1 1 1 1 1 1 1 8
Lee et al. [42] Retrospective 1 1 1 1 1 1 1 1 8

A: Representativeness of the exposed cohort; B: Selection of the non-exposed cohort; C: Ascertainment of exposure; D: Demonstration that outcome of interest was not present at start of study; E: Comparability of cohorts on the basis of the design or analysis; F: Assessment of outcome; G: Was follow-up long enough for outcomes to occur; H: Adequacy of follow up of cohorts.

The 7 prospective studies having no control group were considered at high risk of bias.

Discussion

To the best of our knowledge, this is the first systematic review to have investigated the effect of periodontal treatment in CKD and periodontitis patients in terms of GFR, systemic inflammation, and morbidity and mortality. Some recent systematic review and meta-analysis have demonstrated an association between renal impairment and periodontitis [11, 12, 19], and pointed out the need of RCTs investigating the effect of prevention or periodontal treatment on the severity of renal dysfunction.

Among the 14 prospective studies, only 3 were RCTs and 11 were non-randomized. The objective of the 3 randomized studies was to evaluate the effect of periodontal treatment on systemic inflammation. However, the periodontal treatment differed between each study: oral hygiene instructions and non-surgical periodontal treatment or oral hygiene instructions alone [27], oral hygiene instructions and non-surgical treatment and teeth extractions if necessary [29], or oral hygiene instructions and non-surgical treatment with adjunctive local-delivery antimicrobial therapy and teeth extraction if necessary [34]. Systemic inflammation as assessed by hs-CRP [27, 29] or IL-6 [34] was the primary endpoint. Two were restricted to ESRD patients [29, 34], whereas the third study included all patients with a GFR<60 mL/min:1.73 m2 [27]. Two concluded to a significant effect of the purposed treatment (even oral hygiene instructions only) after treatment compared to baseline [27, 29] or compared to the control group [29] while the third did not [34]. Despite the heterogeneity in the design of the RCTs included in this study, results supported improvement of systemic inflammation (hs-CRP) after periodontal treatment.

Furthermore, RCTs were single centre [27, 29] or single centre pilot studies [34]. Although single centre studies provide the flexibility of approach necessary for clinicians and scientists and an important source for new therapeutic ideas, they may be limited by difficulties in recruiting large numbers of participants. Another problem of such studies is the restrictive selection of studied patients that may hamper the generalization of findings.

About the 11 non-randomized prospective studies, only 4 of these included a control group [26, 30, 36, 37]. The objectives of the latter was to evaluate the effect of periodontal treatment on fatal events in ESRD patients [30], and on systemic inflammation [26, 36] or glomerular filtration rate [37] in patients with different stages of CKD undergoing conservative treatment. Despite the heterogeneity in the design of non-randomized prospective studies and therefore the difficulties to conclude on the influence of periodontal treatment on CKD, results are promising about impact of periodontal treatment on systemic inflammation and GFR.

The primary endpoint differed between studies; inflammation markers were the most frequently used. Measurement of CRP is obviously interesting owing to its association with cardiovascular disease and mortality [46], but periodontitis is an infectious disease that creates overall inflammation in active periods, including increase of CRP levels [6], and therefore improvement of inflammatory markers may not be sufficiently specific to CKD improvement. Furthermore, GFR is used to diagnose CKD and eGFR <60 ml/min/1.73 m2 is associated with subsequent risk of all-cause and cardiovascular mortality, kidney failure, acute kidney injury, and CKD progression in the general population and in populations with increased risk for CVD [47]. However, this was the primary endpoint in only 2 studies. This endpoint should be measured in future studies.

In most studies, the efficacy of the purposed periodontal treatment was evaluated by measuring periodontal indices; this is a prerequisite to conclude on the influence of periodontal treatment on CKD status. However, in the included studies, the number of teeth or the capacity of chewing were not taken in account in the design of studies whereas the decrease of chewing ability will influence the diet of patients [48]. Moreover, periodontal treatment is able to prevent further tooth loss [49]. Not taking in account the number of teeth could be a bias regarding the fact that a liquid alimentation is a negative predictive risk in CKD or ESRD patients. A matching on this confounding factor can be implemented with the simple use of a questionnaire.

About the retrospectives studies, three [3941] showed that ESRD patients receiving intensive periodontal treatment had a significantly lower risk of infections, of cardiovascular diseases and of mortality compared to those without periodontal disease. However, this could also lead to the conclusion that having a treated periodontal disease is better than no disease at all. This highlights a problem with retrospective studies for which it is practically impossible to identify and include patients who are underdiagnosed for periodontal disease.

The heterogeneity of design and protocols between studies does not allow for clear conclusions about the benefit of periodontal treatment in CKD and periodontitis patients in terms of systemic inflammation, GFR, or mortality; further methodologically robust RCTs are needed to demonstrate with a high level of evidence such potential benefit. It is of note that although there are studies that specifically investigated ESRD patients, the others did not distinguish patients on renal disease severity. Future RCTs should separate ESRD patients from those at other stages of CKD as the former are more fragile, often with haemodialysis, and are less likely to follow PTs and regular follow-up; studies including ESRD patients should assess specifically adapted therapies, e.g. prevention or oral hygiene instructions, which can be provided in haemodialysis centres. In addition, basic methodological aspects must be taken into account in order to minimize confounding bias, i.e. selection, attrition, performance, and detection bias. Randomization should include an adequate generation of allocation sequence associated with a clear concealment of allocation. When double-blinding cannot be obtained, a blinded assessment of the endpoints must be performed by a specific adjudication committee. The number of lost to follow-up must be minimized and handling of dropouts and missing data should be specified a priori in the study protocol. In order to avoid Type I Error Rate Inflation, dealing with multiplicity has to be also considered in the first versions of the protocol. Coordinated work and dialogue between nephrologist and periodontist seems obviously extremely important to set up for these future studies.

Periodontal treatment seems to improve CKD status, and results are encouraging especially for the reduction of systemic inflammation. However, further RCTs are needed to confirm these results and to specifically assess the influence of different types of periodontal treatment in CKD patients as well-documented for other systemic diseases such as diabetes [50, 51].

Supporting information

S1 Checklist. PRISMA 2009 checklist.

(TIF)

Acknowledgments

The authors thank Philip Robinson for his careful language review.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global Burden of Severe Tooth Loss: A Systematic Review and Meta-analysis. J Dent Res. 2014. July;93(7_suppl):20S–28S. 10.1177/0022034514537828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Meyle J, Chapple I. Molecular aspects of the pathogenesis of periodontitis. Periodontol 2000. 2015. October;69(1):7–17. 10.1111/prd.12104 [DOI] [PubMed] [Google Scholar]
  • 3.Davé S, Van Dyke T. The link between periodontal disease and cardiovascular disease is probably inflammation. Oral Dis. 2008. March;14(2):95–101. 10.1111/j.1601-0825.2007.01438.x [DOI] [PubMed] [Google Scholar]
  • 4.Könönen E, Gursoy M, Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019. July 31;8(8):1135 10.3390/jcm8081135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cardoso EM, Reis C, Manzanares-Céspedes MC. Chronic periodontitis, inflammatory cytokines, and interrelationship with other chronic diseases. Postgrad Med. 2018. January 2;130(1):98–104. 10.1080/00325481.2018.1396876 [DOI] [PubMed] [Google Scholar]
  • 6.Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol. 2008. April;35(4):277–90. 10.1111/j.1600-051X.2007.01173.x [DOI] [PubMed] [Google Scholar]
  • 7.Preshaw PM. Periodontal disease and diabetes. J Dent. 2009. August;37(8):S575–7. 10.1016/j.jdent.2009.05.019 [DOI] [PubMed] [Google Scholar]
  • 8.Preshaw PM, Bissett SM. Periodontitis and diabetes. Br Dent J. 2019. October;227(7):577–84. 10.1038/s41415-019-0794-5 [DOI] [PubMed] [Google Scholar]
  • 9.Mark Bartold P, Mariotti A. The Future of Periodontal-Systemic Associations: Raising the Standards. Curr Oral Health Rep. 2017. September;4(3):258–62. 10.1007/s40496-017-0150-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Binner C, Wagner J, Schmalz G, Eisner M, Rast J, Kottmann T, et al. Insufficient Oral Behaviour and the High Need for Periodontal Treatment in Patients with Heart Insufficiency and after Heart Transplantation: A Need for Special Care Programs? J Clin Med. 2019. October 12;8(10):1668 10.3390/jcm8101668 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Deschamps-Lenhardt S, Martin-Cabezas R, Hannedouche T, Huck O. Association between periodontitis and chronic kidney disease: Systematic review and meta-analysis. Oral Dis. 2019. March;25(2):385–402. 10.1111/odi.12834 [DOI] [PubMed] [Google Scholar]
  • 12.Chambrone L, Foz AM, Guglielmetti MR, Pannuti CM, Artese HPC, Feres M, et al. Periodontitis and chronic kidney disease: a systematic review of the association of diseases and the effect of periodontal treatment on estimated glomerular filtration rate. J Clin Periodontol. 2013. May;40(5):443–56. 10.1111/jcpe.12067 [DOI] [PubMed] [Google Scholar]
  • 13.Fisher MA, Taylor GW, West BT, McCarthy ET. Bidirectional relationship between chronic kidney and periodontal disease: a study using structural equation modeling. Kidney Int. 2011. February;79(3):347–55. 10.1038/ki.2010.384 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ruospo M, Palmer SC, Craig JC, Gentile G, Johnson DW, Ford PJ, et al. Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrol Dial Transplant. 2014. February;29(2):364–75. 10.1093/ndt/gft401 [DOI] [PubMed] [Google Scholar]
  • 15.Brito F, Almeida S, Figueredo CMS, Bregman R, Suassuna JHR, Fischer RG. Extent and severity of chronic periodontitis in chronic kidney disease patients: Periodontitis and chronic kidney disease. J Periodontal Res. 2012. August;47(4):426–30. 10.1111/j.1600-0765.2011.01449.x [DOI] [PubMed] [Google Scholar]
  • 16.Sekiguchi RT, Pannuti CM, Silva HT Jr., Medina-Pestana JO, Romito GA. Decrease in oral health may be associated with length of time since beginning dialysis. Spec Care Dentist. 2012. January;32(1):6–10. 10.1111/j.1754-4505.2011.00223.x [DOI] [PubMed] [Google Scholar]
  • 17.Chen L-P, Chiang C-K, Peng Y-S, Hsu S-P, Lin C-Y, Lai C-F, et al. Relationship Between Periodontal Disease and Mortality in Patients Treated With Maintenance Hemodialysis. Am J Kidney Dis. 2011. February;57(2):276–82. 10.1053/j.ajkd.2010.09.016 [DOI] [PubMed] [Google Scholar]
  • 18.Kshirsagar AV, Craig RG, Moss KL, Beck JD, Offenbacher S, Kotanko P, et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int. 2009. April;75(7):746–51. 10.1038/ki.2008.660 [DOI] [PubMed] [Google Scholar]
  • 19.Kapellas K, Singh A, Bertotti M, Nascimento GG, Jamieson LM, on behalf of the Perio-CKD collaboration. Periodontal and chronic kidney disease association: A systematic review and meta-analysis: Periodontal and chronic kidney disease. Nephrology. 2019. February;24(2):202–12. 10.1111/nep.13225 [DOI] [PubMed] [Google Scholar]
  • 20.Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009. July 21;6(7):e1000097 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011. October 18;343(oct18 2):d5928–d5928. 10.1136/bmj.d5928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010;http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Google Scholar]
  • 23.Jamieson L, Skilton M, Maple-Brown L, Kapellas K, Askie L, Hughes J, et al. Periodontal disease and chronic kidney disease among Aboriginal adults; an RCT. BMC Nephrol. 2015. December;16(1):181 10.1186/s12882-015-0169-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Study to Assess Lowering the Risk of Heart Problems in Kidney Disease Patients Via Periodontal Treatment. Dent Today. 2015. May;34(5):46, 48. [PubMed] [Google Scholar]
  • 25.Rapone Converti, Santacroce Cesarano, Vecchiet Cacchio, et al. Impact of Periodontal Inflammation on Nutrition and Inflammation Markers in Hemodialysis Patients. Antibiotics. 2019. November 1;8(4):209 10.3390/antibiotics8040209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tasdemir Z, Özsarı Tasdemir F, Gürgan C, Eroglu E, Gunturk I, kocyigit I. The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol. 2018. August;50(8):1519–28. 10.1007/s11255-018-1913-y [DOI] [PubMed] [Google Scholar]
  • 27.Guo N, Lin G. Effects of nonsurgical periodontal therapy on serum inflammatory factor levels in patients with chronic kidney disease and periodontitis. Biomed Res. 2017;28(9):3899–902. [Google Scholar]
  • 28.Almeida S, Figueredo CM, Lemos C, Bregman R, Fischer RG. Periodontal treatment in patients with chronic kidney disease: a pilot study. J Periodontal Res. 2017. April;52(2):262–7. 10.1111/jre.12390 [DOI] [PubMed] [Google Scholar]
  • 29.Fang F, Wu B, Qu Q, Gao J, Yan W, Huang X, et al. The clinical response and systemic effects of non-surgical periodontal therapy in end-stage renal disease patients: a 6-month randomized controlled clinical trial. J Clin Periodontol. 2015. June;42(6):537–46. 10.1111/jcpe.12411 [DOI] [PubMed] [Google Scholar]
  • 30.de Souza CM, Braosi APR, Luczyszyn SM, Olandoski M, Kotanko P, Craig RG, et al. Association Among Oral Health Parameters, Periodontitis, and Its Treatment and Mortality in Patients Undergoing Hemodialysis. J Periodontol. 2014. June;85(6):e169–78. 10.1902/jop.2013.130427 [DOI] [PubMed] [Google Scholar]
  • 31.Kocyigit I, Yucel HE, Cakmak O, Dogruel F, Durukan DB, Korkar H, et al. An ignored cause of inflammation in patients undergoing continuous ambulatory peritoneal dialysis: periodontal problems. Int Urol Nephrol. 2014. October;46(10):2021–8. 10.1007/s11255-014-0716-z [DOI] [PubMed] [Google Scholar]
  • 32.Siribamrungwong M, Yothasamutr K, Puangpanngam K. Periodontal Treatment Reduces Chronic Systemic Inflammation in Peritoneal Dialysis Patients: Periodontal Treatment in Peritoneal Dialysis Patients. Ther Apher Dial. 2013. October;n/a-n/a. 10.1111/1744-9987.12105 [DOI] [PubMed] [Google Scholar]
  • 33.Kiany Yazdi F, Karimi N, Rasouli M, Roozbeh J. Effect of Nonsurgical Periodontal Treatment on C-Reactive Protein Levels in Maintenance Hemodialysis Patients. Ren Fail. 2013. June;35(5):711–7. 10.3109/0886022X.2013.777890 [DOI] [PubMed] [Google Scholar]
  • 34.Wehmeyer MMH, Kshirsagar AV, Barros SP, Beck JD, Moss KL, Preisser JS, et al. A Randomized Controlled Trial of Intensive Periodontal Therapy on Metabolic and Inflammatory Markers in Patients With ESRD: Results of an Exploratory Study. Am J Kidney Dis. 2013. March;61(3):450–8. 10.1053/j.ajkd.2012.10.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Siribamrungwong M, Puangpanngam K. Treatment of Periodontal Diseases Reduces Chronic Systemic Inflammation in Maintenance Hemodialysis Patients. Ren Fail. 2012. March;34(2):171–5. 10.3109/0886022X.2011.643351 [DOI] [PubMed] [Google Scholar]
  • 36.Vilela EM, Bastos JA, Fernandes N, Ferreira AP, Chaoubah A, Bastos MG. Treatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney disease. Clinics. 2011;66(4):657–62. 10.1590/s1807-59322011000400022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Artese HPC, Sousa CO de, Luiz RR, Sansone C, Torres MCM de B. Effect of non-surgical periodontal treatment on chronic kidney disease patients. Braz Oral Res. 2010. December;24(4):449–54. 10.1590/s1806-83242010000400013 [DOI] [PubMed] [Google Scholar]
  • 38.Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME. Periodontitis Is an Important and Occult Source of Inflammation in Hemodialysis Patients. Blood Purif. 2006;24(4):400–4. 10.1159/000093683 [DOI] [PubMed] [Google Scholar]
  • 39.Santos-Paul MA, Neves RS, Gowdak LHW, de Paula FJ, David-Neto E, Bortolotto LA, et al. Cardiovascular risk reduction with periodontal treatment in patients on the waiting list for renal transplantation. Clin Transplant [Internet]. 2019. August [cited 2020 Jun 17];33(8). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.13658 [DOI] [PubMed] [Google Scholar]
  • 40.Huang S-T, Yu T-M, Ke T-Y, Wu M-J, Chuang Y-W, Li C-Y, et al. Intensive Periodontal Treatment Reduces Risks of Hospitalization for Cardiovascular Disease and All-Cause Mortality in the Hemodialysis Population. J Clin Med. 2018. October 11;7(10):344 10.3390/jcm7100344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Huang S-T, Lin C-L, Yu T-M, Wu M-J, Kao C-H. Intensive Periodontal Treatment Reduces Risk of Infection-Related Hospitalization in Hemodialysis Population: A Nationwide Population-Based Cohort Study. Medicine (Baltimore). 2015. August;94(34):e1436 10.1097/MD.0000000000001436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lee C-F, Lin C-L, Lin M-C, Lin S-Y, Sung F-C, Kao C-H. Surgical Treatment for Patients With Periodontal Disease Reduces Risk of End-Stage Renal Disease: A Nationwide Population-Based Retrospective Cohort Study. J Periodontol. 2014. January;85(1):50–6. 10.1902/jop.2013.130015 [DOI] [PubMed] [Google Scholar]
  • 43.Armitage GC. Development of a Classification System for Periodontal Diseases and Conditions. Ann Periodontol. 1999. December;4(1):1–6. 10.1902/annals.1999.4.1.1 [DOI] [PubMed] [Google Scholar]
  • 44.Löe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967. November;38(6):610–6. 10.1902/jop.1967.38.6.610 [DOI] [PubMed] [Google Scholar]
  • 45.Savage A, Eaton KA, Moles DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009. June;36(6):458–67. 10.1111/j.1600-051X.2009.01408.x [DOI] [PubMed] [Google Scholar]
  • 46.Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999. February;55(2):648–58. 10.1046/j.1523-1755.1999.00273.x [DOI] [PubMed] [Google Scholar]
  • 47.van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011. June;79(12):1341–52. 10.1038/ki.2010.536 [DOI] [PubMed] [Google Scholar]
  • 48.Schimmel M, Katsoulis J, Genton L, Müller F. Masticatory function and nutrition in old age. Swiss Dent J. 2015;125(4):449–54. [DOI] [PubMed] [Google Scholar]
  • 49.Raedel M, Priess H-W, Bohm S, Noack B, Wagner Y, Walter MH. Tooth loss after periodontal treatment—Mining an insurance database. J Dent. 2019. January;80:30–5. 10.1016/j.jdent.2018.11.001 [DOI] [PubMed] [Google Scholar]
  • 50.Lira Junior R, Santos C de MM, Oliveira BH, Fischer RG, Santos APP. Effects on HbA1c in diabetic patients of adjunctive use of systemic antibiotics in nonsurgical periodontal treatment: A systematic review. J Dent. 2017. November;66:1–7. 10.1016/j.jdent.2017.08.001 [DOI] [PubMed] [Google Scholar]
  • 51.Nishioka S, Maruyama K, Tanigawa T, Miyoshi N, Eguchi E, Nishida W, et al. Effect of non-surgical periodontal therapy on insulin resistance and insulin sensitivity among individuals with borderline diabetes: A randomized controlled trial. J Dent. 2019. June;85:18–24. 10.1016/j.jdent.2019.04.005 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Bhagwan Dass

30 Oct 2020

PONE-D-20-20992

Effect of periodontal treatment on the glomerular filtration rate, reduction of inflammatory markers and mortality in patients with chronic kidney disease: a systematic review

PLOS ONE

Dear Dr.Kerstin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.,Please address the minor revision as requested by the reviewers.,Your submission  highlights a very good topic in the field of dentistry and Nephrology .

Please submit your revised manuscript by due date , If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Bhagwan Dass, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please ensure that the risk of bias for all the included studies (not just the RCTs) is assessed using a validated tool. For example, by using the Cochrane collaboration’s tool for randomized trials and the Newcastle-Ottawa Scale for nonrandomised studies.

3. Please ensure that references are cited in order. For example, reference 12 doesn’t appear to be cited until the discussion.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript is a well-written review that summarize well the knowledge on CKD and periodontal treatment. It is an up to date work. I have only minor comments.

Minor:

- l40: into consideration

- l48: bacterial

- l63: through thus??

Reviewer #2: The manuscript is good and the data support the conclusions.

The right protocol was used

The statistical analysis was performed appropriately

Article will contribute to knowledge

Minor revision are required

Reviewer #3: This is very interesting article. Really well written and I could not find fault in the approach taken and written to an excellent standard. The link between chronic kidney disease and periodontal disease is one that needs to be investigated further. This article rightly draws attention to the lack of carefully designed randomised clinical trials. Something that my research group are well aware of. Conclusions were valid, this is certainly an approach that should be adopted in the future when treating renal patients that periodontal treatment is provided.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS ONE REVIEW.docx

PLoS One. 2021 Jan 22;16(1):e0245619. doi: 10.1371/journal.pone.0245619.r002

Author response to Decision Letter 0


30 Dec 2020

Response to Reviewers

Journal Requirements

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

The style of the manuscript has been checked and modified as requested.

2. Please ensure that the risk of bias for all the included studies (not just the RCTs) is assessed using a validated tool. For example, by using the Cochrane collaboration’s tool for randomized trials and the Newcastle-Ottawa Scale for nonrandomised studies

The Newcastle-Ottawa Scale has been used (Table 5) to assess the quality of the other included studies (with control groups).

Line 91 (Material and methods section), the following sentence has been added " The quality of each non-randomized study (including at least one control group) was evaluated using the Newcastle-Ottawa Scale [22]. This scale includes 3 categorical criteria with a maximum score of 9 points: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. The quality of each study was rated using the following scoring algorithms: ≥7 points was considered as “high”, 4 to 6 points was considered as “moderate”, and ≤3 point was considered as “poor” quality study."

Line 199 (Results section), the following paragraph " Among the 14 prospective studies, 7 had no control group [24,27,30-32,34,37] and only 3 were RCTs [26,28,33] and could be used for the Cochrane collaboration’s tool for assessing risk of bias in randomized trials. Two studies showed high risk of bias concerned blinding conditions (Table 4) [26,33]. " has been replaced by " Among the 14 prospective studies, 3 were RCTs [27,29,34], 4 included at least one control group [26,30,36,37] and 7 had no control group [25,28,31-33,35,38].

The 3 RCTs could be used for the Cochrane collaboration’s tool for assessing risk of bias in randomized trials. Two studies showed high risk of bias concerned blinding conditions (Table 4) [27,34].

According to the Newcastle-Ottawa Scale, the quality of the 4 prospective studies including at least one control group and of the 4 retrospective studies were considered as moderate quality [26,30,37] and the others as high quality [36, 39-42] (Table 5).

The 7 prospective studies having no control group were considered at high risk of bias."

This modification has led to the addition of a new reference; the numbers of the other references have been modified accordingly.

3. Please ensure that references are cited in order. For example, reference 12 doesn’t appear to be cited until the discussion.

The references have been checked. Reference 12 had been erroneously removed from the introduction section. This has been corrected.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.

The caption for our Supporting Information file (S1 Checklist. Prisma 2009 checklist) has been included at the end of our manuscript. The Prisma Checklist has been modified (column "Reported on page #") in accordance with the present changes of the manuscript (revised version).

Reviewer's Comments

Reviewer #1

This manuscript is a well-written review that summarize well the knowledge on CKD and periodontal treatment. It is an up to date work. I have only minor comments.

Minor:

- l40: into consideration

- l48: bacterial

- l63: through thus??

Thank you. As suggested, modifications have been done.

Reviewer #2

The manuscript is good and the data support the conclusions.

The right protocol was used

The statistical analysis was performed appropriately

Article will contribute to knowledge

Minor revision are required

Reviewer #3

This is very interesting article. Really well written and I could not find fault in the approach taken and written to an excellent standard. The link between chronic kidney disease and periodontal disease is one that needs to be investigated further. This article rightly draws attention to the lack of carefully designed randomised clinical trials. Something that my research group are well aware of. Conclusions were valid, this is certainly an approach that should be adopted in the future when treating renal patients that periodontal treatment is provided.

Reviewer Comments submitted as an attachment file

Introduction

Line 52: kindly change i.e. to for example (Because there are other associations between periodontitis and systemic diseases)

Line 58: prevention of what? (Suggestion: prevention of periodontal disease

Line 63: kindly remove ‘Through thus’(Suggestion using clinical parameters)

Thank you for the suggestions. Modifications have been made accordingly.

Materials and methods

Study selection

Line 68-72: Any article where participants had other systemic diseases already associated with periodontitis like D/M, CVD, etc should have been excluded from this study

We agree that these other systemic diseases need to be taken into account. As indicated in our discussion, further methodologically robust RCTs are needed. Nevertheless, CKD patients often suffer from co-morbidities, especially ESRD patients. We have chosen, in this review, to keep all the studies in order to take into account this clinical aspect, and to help practitioners in the management of their CKD patients.

Search Strategy

LINES 80-83: What did you do with the articles that were duplicated since there was a likelihood of that as 2 different search engines were used (PUBMED and Web of Science)?

This should be reported here as well as under study selection

The duplicates are mentioned in the results section (in the paragraph Study selection) and in the flow diagram (Fig 1) as advised by following the PRISMA guidelines.

Data collection

Line 88 /89: kindly delete risk of, if, found, involved. Kindly replace with ‘only each risk of bias……………………….in the first instance; where consensus could not be reached, a third reviewer was consulted’

The sentence has been modified as suggested.

Results

Study design

Line 126: How sure were the authors of study 25 that the result they got was not due to the periodontal effect of diabetes since a 2-way relationship had been established between periodontitis and diabetes mellitus? Shouldn’t this article have been discarded in order to avoid bias? Kindly state this as a limitation to the study

In the study 25 (study 25 has become study 26 after the addition of a reference), the experimental group (Chronic Kidney Disease + Diabetes + Periodontitis) was compared to 2 control groups, one including patients with Diabetes + Periodontitis and one including patients with Periodontitis only, taking into consideration the relationship between periodontitis and diabetes mellitus. Following the Journal requirements, the quality of this study has now been assessed using the Newcastle-Ottawa scale.

Line 142: Assessment on renal disease and systemic inflammation: Kindly replace with ‘assessment of ………….

Periodontal assessment criteria and periodontal treatment efficacy evaluation

Line 171: kindly delete ‘for’

172: kindly replace ‘has been’ with ‘was’

267: priori………………priority

Thank you for the suggestions. Modifications have been made accordingly.

Line 267 (line 282 in the revised version), "a priori" has been written in italics to avoid confusion

Attachment

Submitted filename: Response to Reviewers .docx

Decision Letter 1

Bhagwan Dass

5 Jan 2021

Effect of periodontal treatment on the glomerular filtration rate, reduction of inflammatory markers and mortality in patients with chronic kidney disease: a systematic review

PONE-D-20-20992R1

Dear Dr. Gritsch,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Bhagwan Dass, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Bhagwan Dass

7 Jan 2021

PONE-D-20-20992R1

Effect of periodontal treatment on the glomerular filtration rate, reduction of inflammatory markers and mortality in patients with chronic kidney disease: a systematic review

Dear Dr. Gritsch:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Bhagwan Dass

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2009 checklist.

    (TIF)

    Attachment

    Submitted filename: PLOS ONE REVIEW.docx

    Attachment

    Submitted filename: Response to Reviewers .docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES